$SGLT-2 inhibitors on prognosis and health-related quality of life in patients with heart failure and preserved ejection fraction: A systematic review and meta-analysis$

SGLT-2 inhibitors on prognosis and health-related quality of life in patients with heart failure and preserved ejection fraction: A systematic review and meta-analysis

BackgroundHeart failure with preserved ejection fraction (HFpEF) is becoming the main subtype of heart failure, but lacks proven effective therapies. Sodium-glucose cotransporter-2 (SGLT-2) inhibitor, a new kind of oral glucose-lowering agent, shows a great effect on improving cardiovascular outcome...

Full description

Bibliographic Details
Main Authors:	Danning Yang, Yu Zhang, Jie Yan, Ming Liu, Fengshuang An
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2022-09-01
Series:	Frontiers in Cardiovascular Medicine
Subjects:	sodium-glucose cotransporter-2 inhibitors heart failure with preserved ejection fraction prognosis health-related quality of life meta-analysis
Online Access:	https://www.frontiersin.org/articles/10.3389/fcvm.2022.942125/full

Similar Items

Sodium-glucose cotransporter 2 inhibitors in heart failure with preserved ejection fraction: A meta-analysis of randomized controlled trials
by: Hidekatsu Fukuta, et al.
Published: (2022-10-01)

Reshaping Treatment of Heart Failure with Preserved Ejection Fraction
by: Nikolaos Karamichalakis, et al.
Published: (2022-06-01)

Efficacy of Sodium-Glucose Cotransporter 2 Inhibitors in Heart Failure with a Preserved Ejection Fraction: A Meta-Analysis of Randomized Controlled Trials
by: Yake Lou, et al.
Published: (2022-10-01)

Is it time for class I recommendation for sodium-glucose cotransporter-2 inhibitors in heart failure with mildly reduced or preserved ejection fraction?: An updated systematic review and meta-analysis
by: Sukrit Treewaree, et al.
Published: (2023-02-01)

Scientific evidence of sodium-glucose cotransporter-2 inhibitors for heart failure with preserved ejection fraction: an umbrella review of systematic reviews and meta-analyses
by: Runmin Li, et al.
Published: (2023-05-01)

SGLT2i versus ARNI in heart failure with reduced ejection fraction: a systematic review and meta‐analysis
by: Yuling Yan, et al.
Published: (2021-06-01)

Sodium‐glucose cotransporter‐2 inhibitors in heart failure: an updated meta‐analysis
by: Yang Cao, et al.
Published: (2022-06-01)

Heart Failure with Preserved Ejection Fraction: How to Deal with This Chameleon
by: Fabiana Lucà, et al.
Published: (2024-02-01)

Improvement in Left and Right Ventricular Function after Introduction of SGLT2 Inhibitors in Heart Failure Outpatients with Reduced Ejection Fraction
by: Gianmarco Alcidi, et al.
Published: (2023-10-01)

Prescribing patterns of SGLT-2 inhibitors for patients with heart failure: A two-center analysis
by: Teja Chakrala, et al.
Published: (2023-04-01)

Diabetes Mellitus and Heart Failure
by: Wun-Zhih Siao, et al.
Published: (2022-10-01)

Heart failure with preserved ejection fraction – onset
by: Branimir Kanazirev
Published: (2021-07-01)

SGLT2 inhibitors for patients with heart failure with preserved ejection fraction in China: a cost-effectiveness study
by: He Lu, et al.
Published: (2023-09-01)

Left Ventricular Strain in Heart Failure with Preserved Ejection Fraction
by: Madhu Shukla, et al.
Published: (2023-01-01)

Prevalence and prognosis of frailty in older patients with stage B heart failure with preserved ejection fraction
by: Chen Meng, et al.
Published: (2023-04-01)

Emerging concepts in heart failure treatment and management: focus on SGLT2 inhibitors in heart failure with preserved ejection fraction
by: Andrea Beatriz De Lorenzi, et al.
Published: (2023-01-01)

Sodium-glucose cotransporter type 2 inhibitors in patients with heart failure with preserved ejection fraction: a systematic review and meta-analysis
by: Evgeny M. Mezhonov, et al.
Published: (2023-04-01)

High triglyceride-glucose (TyG) index is associated with poor prognosis of heart failure with preserved ejection fraction
by: Qing Zhou, et al.
Published: (2023-09-01)

Prognostic Value of Anxiety Between Heart Failure With Reduced Ejection Fraction and Heart Failure With Preserved Ejection Fraction
by: Tin‐Kwang Lin, et al.
Published: (2019-06-01)

Estimated Population Prevalence of Heart Failure with Reduced Ejection Fraction in Spain, According to DAPA-HF Study Criteria
by: Anna Camps-Vilaró, et al.
Published: (2020-07-01)

Predictors and Outcomes of Heart Failure With Preserved Ejection Fraction in Patients With a Left Ventricular Ejection Fraction Above or Below 60%
by: Akito Nakagawa, et al.
Published: (2022-08-01)

Retrospective analysis of SGLT2 inhibitors in heart failure with preserved ejection fraction
by: John S. Clemmer, et al.
Published: (2023-06-01)

Obesity paradox in chronic heart failure with moderately reduced or preserved left ventricular ejection fraction: impact on a prognosis for patients according to a five-year follow-up
by: P. P. Bidzilya, et al.
Published: (2023-07-01)

Phosphodiesterase inhibitor for heart failure with preserved ejection fraction: A systematic review and meta-analysis
by: Zhu Chen, et al.
Published: (2022-08-01)

Cost-Effectiveness of Empagliflozin in Combination with Standard Care versus Standard Care Only in the Treatment of Heart Failure Patients in Finland
by: Hallinen T, et al.
Published: (2023-01-01)

Comparable effect of tolvaptan in heart failure patients with preserved or reduced ejection fraction
by: Shunsuke Kiuchi, et al.
Published: (2020-02-01)

Diagnostic and prognostic implications of heart failure with preserved ejection fraction scoring systems
by: Vibhu Parcha, et al.
Published: (2021-06-01)

Lowering Uric Acid May Improve Prognosis in Patients With Hyperuricemia and Heart Failure With Preserved Ejection Fraction
by: Masami Nishino, et al.
Published: (2022-10-01)

Recurrent heart failure hospitalizations in heart failure with preserved ejection fraction: an analysis of TOPCAT trial
by: Qi Wang, et al.
Published: (2024-02-01)

Change in Nutritional Status during Hospitalization and Prognosis in Patients with Heart Failure with Preserved Ejection Fraction
by: Akihiro Sunaga, et al.
Published: (2022-10-01)

Impact of intravenous ferric carboxymaltose on heart failure with preserved and reduced ejection fraction
by: Raquel López‐Vilella, et al.
Published: (2022-02-01)

Heterogeneous Metabolic Response to Exercise Training in Heart Failure with Preserved Ejection Fraction
by: Martin Bahls, et al.
Published: (2019-04-01)

Mean corpuscular haemoglobin concentration and outcomes in heart failure with preserved ejection fraction
by: Manting Choy, et al.
Published: (2023-04-01)

Serum uric acid: A risk factor for right ventricular dysfunction and prognosis in heart failure with preserved ejection fraction
by: Xiang-liang Deng, et al.
Published: (2023-03-01)

Mean platelet volume: a prognostic marker in heart failure with preserved ejection fraction
by: Nassiba Menghoum, et al.
Published: (2023-12-01)

The Role of Sodium-Glucose Cotransporter-2 Inhibitors in Heart Failure Management: The Continuing Challenge of Clinical Outcome Endpoints in Heart Failure Trials
by: Luxi Ji, et al.
Published: (2023-03-01)

Viewing the future research directions of heart failure from ge's phenotyping of heart failure with preserved ejection fraction
by: Yan-Xiang Zang, et al.
Published: (2021-01-01)

Molecular biomarker profile of heart failure with mid-range and preserved ejection fraction in patients with type 2 diabetes
by: D. A. Lebedev, et al.
Published: (2020-11-01)

Heart Failure with Preserved Ejection Fraction (HFpEF): Part 2 Review of Experience and Evidence with SGLT-2 Inhibitors and Commentary
by: Soneil Guptha, Eteri Tsetskhladze
Published: (2023-06-01)

Sodium-glucose co-transporter 2 inhibitors in heart failure with mildly reduced or preserved ejection fraction: an updated systematic review and meta-analysis
by: Yintang Wang, et al.
Published: (2022-12-01)